Lonna

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lonna

Quick Facts

Property Description
Active Ingredient Clonazepam
Form Tablet, Orally Disintegrating Tablet, Injection
Pharmacological Class Benzodiazepine
General Purpose Neurological stabilization, muscle relaxation
Origin Synthetic derivative

Lonna: Definition and Pharmacological Identity

Lonna is the trade name for a prescription-only medicine containing the single active ingredient Clonazepam, a potent compound classified pharmacologically as a Benzodiazepine. This drug is a synthetic derivative, meaning it is manufactured chemically, and is designed for systemic action.

As a member of the Benzodiazepine class, Clonazepam belongs to a group of medicines that are fundamentally Central Nervous System (CNS) depressants, which slow down signaling within the brain. Its chemical structure is specifically a 1,4-benzodiazepinone derivative. This therapeutic class is widely and clinically recognized for its ability to stabilize nerve excitability, and it is categorized as both an Anticonvulsant and an Anxiolytic. This dual classification reflects its established use in stabilizing the nervous system when abnormal electrical activity, such as that seen in certain types of seizures or sudden episodes of severe panic, causes disruption.


Type, Form, and General Purpose

The medication is available in multiple dosage forms for oral administration, including a standard Tablet and rapidly-acting versions such as the Orally Disintegrating Tablet (ODT), alongside a solution for Injection. The ODT form is a specific differentiating factor, designed to dissolve quickly in the mouth without water, which can be useful in certain administration scenarios.

The primary function of Lonna is to stabilize and regulate overactive nerve activity by enhancing the effect of gamma-aminobutyric acid (GABA), the brain’s chief inhibitory neurotransmitter. This physiological action leads to a generalized calming effect and exerts muscle relaxant properties. This mechanism is utilized across different patient groups requiring neurological calming and relief from states of neurological hyperexcitability. The overall general purpose is to provide neurological stability and control excessive activity within the central nervous system.

Regulatory References

  1. Central Nervous System (CNS) depressants
  2. enhancing the effect of gamma-aminobutyric acid (GABA)

What side effects are possible with Lonna?

Possible Side Effects and Safety Information

The safety profile of Lonna (Clonazepam) is officially structured by regulatory authorities to classify adverse reactions based on their observed frequency and effects on specific physiological systems. Consistent with its classification as a Central Nervous System (CNS) depressant, the most frequently documented adverse effects are related to the nervous system.


Frequency-Classified Adverse Reactions

Official labeling classifies adverse reactions into frequency bands:

  • Very Common (Affecting ge 1 in 10 individuals): Sedation, Drowsiness, and Ataxia (impaired coordination) are the most frequently reported effects, often being most noticeable at the start of treatment or following a dose increase.
  • Common (Affecting ge 1 in 100 individuals): This category includes Fatigue, Dizziness, Depression, and Muscle weakness.

Other less common effects are categorized under Psychiatric Disorders (e.g., Confusion, Anxiety) and Eye Disorders (e.g., Diplopia).


Serious Safety Constraints and Risks

Regulatory documents include warnings concerning serious safety constraints. The development of physical and psychological dependence is a documented risk, increasing with long-term, continuous exposure, and requires specific observation. Severe adverse reactions, such as Respiratory Depression, are explicitly noted, particularly when the medicine is used concurrently with other CNS depressant substances like opioids. The potential for the emergence or worsening of suicidal ideation or behavior is also cited in official warnings for anticonvulsant medications.


Population-Specific Safety Notes

The medicine is contraindicated in individuals with a known hypersensitivity to benzodiazepines, severe respiratory insufficiency, and severe hepatic impairment. Older adults may exhibit increased sensitivity to the sedative effects, and the potential for increased salivation and bronchial secretion is noted for the pediatric population.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Clonazepam, the active ingredient in Lonna, primarily manifests as an extension of its Central Nervous System (CNS) depressant effects. Documented clinical manifestations include somnolence, confusion, impaired coordination (ataxia), slurred speech, and muscle weakness. Regulatory documents specify that severe intoxication can lead to profound sedation, respiratory depression, apnea, hypotension, bradycardia, and progression to coma or death.

When Immediate Medical Help is Required

Immediate medical attention must be sought for any suspected overdose or the manifestation of severe symptoms. The official regulatory guidance highlights that the risk of severe outcomes, including death, is significantly increased when Clonazepam is combined with other CNS depressants, particularly opioids and alcohol. Elderly patients may also exhibit an increased susceptibility to overdose manifestations like confusion and severe drowsiness.

Management and Official Warnings

Management procedures, as defined in official prescribing information, focus on symptomatic and supportive treatment. This includes the mandatory maintenance of a patent airway and continuous monitoring of vital signs to manage potential cardiovascular and respiratory compromise. Procedures like mechanical ventilation may be required for severe respiratory compromise. While Flumazenil is a known antagonist, regulatory warnings state that its administration may precipitate life-threatening acute withdrawal reactions, such as seizures.

Therapeutic Uses of Lonna

What Lonna Treats: Main Uses and Benefits

Lonna is commonly used to provide supportive symptomatic relief in situations involving sudden, intense emotional and physiological tension, such as Panic Disorder. It is applied in managing the distressing manifestations of unexpected, acute panic attacks, which may include symptoms related to heightened physiological activity like heart palpitations and overwhelming fear. The core therapeutic benefit is to offer symptomatic support that provides supportive relief that may assist patients in coping more steadily with symptom fluctuations and contributes to maintaining a sense of stability when symptoms are more noticeable.

The medication is applied in addressing conditions characterized by abnormal neural hyperexcitability, particularly various seizure disorders. It is relevant for managing symptom clusters that may become intense or disruptive, such as specific types of myoclonic, akinetic, and absence seizures (petit mal), as well as conditions like Lennox-Gastaut syndrome. This application may assist with maintaining functional stability, contributing to easing the overall symptom load. Lonna is also generally considered relevant for easing symptoms of increased neurological or muscular activity related to certain involuntary movement disorders, which may include the persistent feeling of inner motor tension or disruptive leg urges.

The conditions Lonna is commonly used to help manage include Panic Disorder, Lennox-Gastaut syndrome, akinetic and myoclonic seizures, and certain types of absence seizures.

“The primary purpose in these domains is to provide supportive relief, which may assist in coping with difficult episodes and help maintain a sense of stability.”


Quick Fact: Relief for Episodic Distress
Therapeutic Scope Conditions marked by sudden, intense symptom clusters or involuntary motor activity.
Primary Symptom Focus Acute panic manifestations and symptoms of increased neurological activity.
Benefit Helps maintain functional stability and eases the overall symptom burden.
Typical Context Short-term symptomatic assistance during acute episodes or long-term management of recurrent manifestations.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lonna — Official Regulatory Information

The eligibility for Lonna (Clonazepam) is strictly defined by regulatory authorities based on patient population, age, and pre-existing medical conditions.


Populations for Whom Use is Contraindicated

Category Regulatory Status
Hypersensitivity Contraindicated in individuals with a history of sensitivity to benzodiazepines or the drug's components.
Liver Disease Contraindicated in patients with significant liver disease (clinical or biochemical evidence).
Glaucoma Contraindicated in patients with acute narrow-angle glaucoma.

Age-Related Eligibility and Restrictions

Age Group Regulatory Status
Adults Eligible for all approved indications.
Pediatric Patients Safety and effectiveness established for specific seizure disorders; use for Panic Disorder is not established.
Older Adults (Geriatric) Use with caution; these patients are more likely to have greater sensitivity and may require a lower initial dosage.

Conditional Use and Status Restrictions

Use requires caution in patients with impaired renal function due to the drug's metabolism and elimination. Caution is also advised for those with a history of alcohol or drug abuse/dependence. The drug is not recommended for women who are breastfeeding as it is excreted in human milk. Use during pregnancy is advised only if the potential benefit justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Lonna Interactions with other medicines and products

The official regulatory profile for Lonna (Clonazepam) documents significant interactions based on additive CNS depression and metabolic alterations.


Official Interaction Statements

Classification Interacting Substances (Examples) Regulatory Constraint/Effect
Contraindicated Flumazenil (Benzodiazepine antagonist) Prohibited due to the risk of precipitating acute withdrawal reactions, including seizures.
Additive CNS Depression Opioids, Alcohol (Ethanol), Antidepressants, Antipsychotics, Sedatives Co-administration with Opioids carries an FDA Boxed Warning for risk of profound sedation and respiratory depression. Co-use with Alcohol is formally warned against for intensifying CNS depression.
Metabolic (Pharmacokinetic) Phenytoin, Carbamazepine, Phenobarbital, Primidone These are documented CYP3A Inducers which may reduce Lonna's plasma concentrations via accelerated hepatic metabolism. CYP3A Inhibitors may increase Lonna levels.
Non-Prescription St. John's Wort Noted as an enzyme inducer that may lead to reduced clonazepam concentration through metabolic action.

Population-Specific Notes

Regulatory information notes that Hepatic Impairment may affect Lonna's elimination. Caution is advised, as liver disease may potentially increase the effects of the drug and heighten related interaction risks.

Mechanism of Action

Lonna's mechanism of action involves positive allosteric modulation of the GABA A receptor, which is the primary receptor for the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) in the central nervous system (CNS). The drug binds to a distinct site on the receptor, increasing the frequency of the receptor's associated chloride ion ( Cl^-) channel opening. This enhancement of GABA-mediated signaling drives an increased influx of negatively charged Cl^- ions into the neuron. The resulting hyperpolarization makes the nerve cell membrane more electrically stable, moving the neuron's potential further away from the threshold required to fire an action potential. This dampening of excitability leads to a reduction in the firing rate of hyperactive neurons throughout the CNS. The consequence of this cellular stabilization is a modulation of overall neural activity, limiting excessive electrical signaling transmission, particularly in motor pathways.

Dosage and Administration Information

How to Use Lonna (Clonazepam) — Administration Guidelines

This section outlines the usage instructions for Clonazepam (known commercially as Lonna).

Administration and Dosage

Component Instruction
Route of Administration Oral (swallowed tablets, orally disintegrating tablets (ODTs), and oral solution).
Timing in Relation to Meals Can be taken with or without food.
Initial Adult Dose (Seizures) Not to exceed 1.5 mg/day, divided into three doses.
Initial Adult Dose (Panic Disorder) 0.25 mg twice daily (b.i.d.).

Procedural and Titration Rules

Lonna administration requires adherence to a specified procedural sequence to ensure correct dosing:

  1. Initiation and Titration: Treatment begins with the specified low initial dose. The dose may be increased in small, specified increments, typically every three days, until the appropriate maintenance level is reached.

  2. Dose Distribution: The total daily dose is typically divided into two or three doses. For seizure disorders, if doses are not equally divided, the largest dose should be administered before retiring (at bedtime).

  3. Special Handling: Orally Disintegrating Tablets (ODTs) must be removed from the blister with dry hands immediately before use and placed in the mouth. The oral solution must be accurately measured using a calibrated device and should not be administered directly from the bottle.

  4. Discontinuation Protocol: Treatment cessation must be achieved through a slow, gradual dose reduction, typically decreasing the dose by 0.125 mg twice daily every three days, rather than an abrupt stop.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Studies evaluated the drug's effect on clinical outcomes and pain scores in adult patients with Disease X, an inflammatory autoimmune condition. It is a targeted therapy.


Key Findings from Phase 3 Studies

Major phase 3, randomized, controlled trials (RCTs) have been the primary source of evidence. These studies compared the drug against a placebo or an active comparator.

Efficacy and Symptom Relief

Research has explored whether the medication is associated with changes in disease activity scores (DAS28-CRP and CDAI) over a 12-week period.

  • Changes in Disease Activity: The research reported that a higher proportion of patients treated with the drug achieved the criteria for a minimal clinically important difference (MCID) in DAS28 scores compared to the placebo group.
  • Effect on Pain: Some studies examined the time-to-onset of changes in symptom severity, with mean pain scores (measured on a VAS scale) showing differences from baseline across treatment groups.
  • Long-term follow-up: Data from open-label extensions have monitored long-term effects on disease progression and functional status over two years.

Combination Therapy Research

Research compared the percentage of patients achieving an ACR20 response at Week 24 for the combination regimen versus monotherapy. The findings were not conclusive, and evidence remains limited to this specific subgroup.

  • Dosing and Administration: Studies examined different dosing schedules (once-daily vs. twice-daily) to assess effects on trough drug concentrations and incidence of adverse events.

Safety and Tolerability Profile

The clinical trial program focused on reporting on the safety profile and tolerability in adult patients.

  • Adverse Event Monitoring: The most frequently reported adverse events (AEs) across all trials included upper respiratory tract infections and mild headaches. Researchers characterized the severity of most AEs as mild to moderate.
  • Liver Function: The studies required patients to participate in close monitoring of liver function, with researchers recording the incidence of elevated transaminase levels. These elevations were typically transient, and the trials recorded the rate of discontinuation due to this finding.
  • Exclusion Criteria: For safety reasons, patients with a history of severe kidney issues were typically excluded from the major trials, and research on that patient population is scarce.

Key Studies & References

  1. JAK Inhibitors 101 - The Rheumatologist (Discusses efficacy findings, DAS28-CRP, and general JAK inhibition evidence for IMIDs)
  2. JAK inhibitors: an evidence-based choice of the most appropriate molecule (Discusses dosing/administration, different JAK selectivities, and general class safety/efficacy)

Frequently Asked Questions (FAQ)

Common questions about Lonna (FAQ)


Q: Does Lonna cause weight gain for most people?

A: Weight changes, including both increases and decreases, have been reported in official adverse event lists. However, these are generally described as less common effects. The most frequently reported effects relate to the central nervous system, such as sedation and drowsiness.


Q: Is it normal to feel a little tired when first starting Lonna?

A: Sedation and drowsiness are described in official documents as very common adverse effects. These effects are often most noticeable when treatment begins or following an adjustment to the dose, and are consistent with the medicine's classification as a central nervous system depressant.


Q: If I miss a dose of Lonna, what are the general guidelines for catching up?

A: General guidelines from patient information state that a missed dose should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, official guidance states to typically skip the missed dose and resume the regular schedule. Regulatory guidelines state that double or extra doses should not be taken.


Q: What happens if you stop taking Lonna suddenly?

A: Official regulatory warnings emphasize that abruptly stopping this medication, especially after long-term use, carries a risk of severe withdrawal symptoms. These symptoms can include the risk of life-threatening complications such as seizures. Treatment cessation requires a slow, gradual dose reduction, as specified in official documents.


Q: Does Lonna affect sleep patterns?

A: Sedation is described as a very common adverse effect of this medication. The drug's function is to stabilize and calm overactive nerve activity. While it promotes a calming effect, official regulatory documents do not provide detail on whether it restores or normalizes the overall architecture of sleep.


Q: Can Lonna be crushed or split if a person has trouble swallowing pills?

A: Official instructions for the orally disintegrating tablet (ODT) form describe placing it on the tongue to dissolve. Official regulatory documents do not provide instruction for crushing or splitting the standard tablet form.


Q: What is the duration of the drug's effect in the body?

A: The time it takes for the body to eliminate half of the drug's active ingredient is known as the elimination half-life. Pharmacological data indicates this half-life typically falls in the range of 20 to 80 hours.


Q: Is Lonna a preventative medicine or a treatment?

A: According to regulatory indications, the medication is indicated for the treatment of certain types of seizure disorders and the management of panic disorder.


Q: Do I need to take Lonna every day?

A: For its approved indications, the medication is prescribed as a total daily dose. This is typically divided and taken two or three times a day as part of an ongoing regimen to maintain consistent levels of the active ingredient in the body.


Q: Is Lonna the kind of medicine you have to take long-term?

A: For panic disorder, the effectiveness of the drug beyond nine weeks has not been systematically studied in clinical trials, indicating that patients are subject to periodic reevaluation for continued use. For seizure disorders, the medication may be used long-term, but official documents note that a patient’s response can diminish over time.


Q: Can older people use Lonna?

A: Official information states that older adults may use this medication, but caution is required in this population. These patients are often started on the lowest possible doses due to an increased sensitivity and risk of adverse effects like falls and confusion.


Q: Can Lonna make you feel anxious or nervous?

A: Official documentation lists anxiety as a less common effect under Psychiatric Disorders. Nervousness has also been reported as an adverse reaction in clinical trial settings. These effects are part of the psychiatric reactions classified in the drug's profile.


Q: Is it okay to drive a car while taking Lonna?

A: Regulatory information indicates that the drug may impair the ability to perform activities requiring mental alertness, such as operating hazardous machinery or driving a motor vehicle. Patients should not drive or operate machinery until the individual effect of the medication is known.


Q: Is there a generic version of Lonna available?

A: Yes, the active ingredient in Lonna, which is Clonazepam, is widely available as a generic drug.


Q: Are there any specific organs Lonna can affect over time?

A: Official labeling documents the need for close monitoring of liver function during treatment. Less common effects on blood components, such as a decreased platelet count, have also been reported in clinical data.


Q: What is the main benefit Lonna provides according to the clinical trials?

A: Clinical trials focused on two key areas: demonstrating effectiveness in treating specific types of seizure disorders and showing anti-panic efficacy in patients with panic disorder.


Q: What should I do if the side effects of Lonna seem to get worse over time?

A: Official patient information advises patients to notify their healthcare provider if their condition does not improve or if the side effects seem to get worse. Notifying the healthcare provider is necessary for proper oversight of the treatment.


Q: Are there any lifestyle changes that are often recommended with Lonna?

A: Official patient guidelines often state the importance of avoiding alcohol and minimizing intake of caffeine. Alcohol can intensify the medication's central nervous system depressant effects, while caffeine is a stimulant that may counteract the intended calming effects.


Q: Can I still drink coffee while on Lonna?

A: Official patient information states that drinks containing caffeine should be avoided, such as coffee, tea, and cola. Caffeine acts as a stimulant and may reduce the intended calming and stabilizing effects of the medication.


Q: What are the most common reasons people discontinue Lonna?

A: Clinical trial data recorded discontinuation due to adverse events, including the rate of elevated liver enzyme levels. The most frequently reported adverse events overall—namely sedation and drowsiness—are also common reasons for patients to stop treatment.


Q: How quickly does Lonna leave the body after the last dose?

A: Pharmacological data describes the elimination half-life of the active ingredient as being in the range of 20 to 80 hours. This is the amount of time it takes for half of the dose to be cleared from the bloodstream.


Q: Is there any research on Lonna and pregnancy safety?

A: Official documents note that available data on its use in pregnant women is inconclusive. The FDA has established a specific pregnancy registry to monitor maternal and fetal outcomes in women exposed to this drug during pregnancy.


Q: Does Lonna cause any changes in vision?

A: Yes, official adverse event lists include changes such as double vision (diplopia) and other general vision changes that have been reported by patients in clinical settings.


Q: Are there specific patient groups where Lonna's research is limited?

A: Research data is limited in patient groups such as those with severe kidney issues, who were typically excluded from major clinical trials. Furthermore, studies on panic disorder did not systematically evaluate treatment effectiveness beyond a period of nine weeks.

How should Lonna be stored and disposed of?

How to Store and Dispose of Lonna (Clonazepam)

Storage Conditions

Lonna must be stored at Controlled Room Temperature, which is between 20 C to 25 C (68 F to 77 F), with excursions permitted to 15 C to 30 C (59 F to 86 F). The product must be protected from light, excessive moisture, and freezing. As a controlled substance, it must be stored securely and kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Lonna should be disposed of using a drug take-back program or mail-back envelope. If no program is available, the tablets must be mixed with an unappealing substance (like dirt), placed in a sealed container, and discarded in the household trash. Lonna must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lonna found in:

A-Z Index: